xilonix
mAbexperimental
Bermekimab is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis. — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01767857)
Timeline
Indications
Mechanism of action
- Interleukin-1 alphaINHIBITOR
IL1A inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBermekimab ↗
Also known as
- xilonix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03207724 | Phase 1 | Oct 16, 2017 | Cedars-Sinai Medical Center, Ipsen, XBiotech, Inc. |
| NCT02138422 | Phase 3 | Jul 1, 2014 | Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, XBiotech, Inc. |
| NCT01965613 | Phase 2 | Jan 1, 2014 | XBiotech, Inc. |
| NCT01767857 | Phase 3 | Mar 1, 2013 | Stanford University, XBiotech, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| XBiotech, Inc. | For profit | 4 | 3 | 3 | 2013 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Ipsen | For profit | 1 | 0 | 1 | 2017 |
| Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1